Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review, Meta‐Analysis, and Meta‐Regression
Transplant Infectious Disease · 2025
DOI: 10.1111/tid.70006 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Abdullah Yousef Aldalati und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Antiviral Agents, Acetates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 44 Literaturangaben.
Abstract (Originalsprache)
Objective
Letermovir (LTV) is a novel antiviral agent approved by the FDA in 2017 for CMV prophylaxis in adult CMV‐seropositive allogeneic hematopoietic stem cell transplantation (allo‐HSCT) recipients and approved for pediatric use in 2024. This study systematically evaluates the efficacy and safety of LTV prophylaxis for CMV infection in pediatric allo‐HSCT recipients.
Methods
We systematically searched PubMed, Scopus, Web of Science, Embase, and Cochrane Library up to December 2024 for studies that evaluated the use of LTV prophylaxis in pediatric allo‐HSCT recipients. We conducted single‐arm meta‐analysis using Open Meta Analyst software and double‐arm meta‐analysis using R Studio. We pooled the dichotomous outcomes as event and total using the fixed‐effects model.
Results
Twelve articles were included in the analysis. The single‐arm meta‐analysis indicated that the prophylactic use of LTV against CMV among pediatrics was associated with a 10.9% (95% CI: 0.065, 0.153) infection rate without any disease occurrence. The percentage of patients who discontinued the drug due to adverse reactions was only 2.4% (95% CI: 0.003, 0.045), and all‐cause mortality was 7.9% (95% CI: 0.032, 0.126). The double‐arm meta‐analysis results indicated that the incidence of CMV infection was significantly lower in the LTV group in comparison to the control group (RR: 0.29; 95% CI: 0.16, 0.56; p < 0.001).
Conclusion
LTV has demonstrated safety and efficacy in preventing CMV infection and disease among high‐risk pediatric patients. Future large scale randomized trials are necessary to validate the findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
- Faculty of Medicine, Al- Balqa' Applied University, Salt, Jordan.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Lahore General Hospital, Lahore, Punjab, Pakistan.
- Department of Pediatrics of Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital, St. Louis, Missouri, USA.
- Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID-Profile: Abdullah Yousef Aldalati, Mohammad Abuassi
Zitieren
APA
Aldalati, A. Y., Hussein, A. M., Balbaa, E., Hammadeh, B. M., Idrees, M., Aloudat, O., Albliwi, M., Abuassi, M., & Sultan, I. (2025). Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review, Meta‐Analysis, and Meta‐Regression. Transplant Infectious Disease. https://doi.org/10.1111/tid.70006
Vancouver
Aldalati AY, Hussein AM, Balbaa E, Hammadeh BM, Idrees M, Aloudat O, et al. Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review, Meta‐Analysis, and Meta‐Regression. Transplant Infectious Disease. 2025. doi:10.1111/tid.70006
BibTeX
@article{Aldalati2025,
author = {Aldalati, Abdullah Yousef and Hussein, Ayham Mohammad and Balbaa, Elsayed and Hammadeh, Bara M and Idrees, Muhammad and Aloudat, Osama and Albliwi, Moath and Abuassi, Mohammad and Sultan, Iyad},
title = {Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Pediatric Hematopoietic Stem Cell Transplantation Recipients: A Systematic Review, Meta‐Analysis, and Meta‐Regression},
journal = {Transplant Infectious Disease},
year = {2025},
doi = {10.1111/tid.70006}
}
EUVIMED